In an interview with pharmaphorum, Dion Warren, head of Takeda's European oncology business, said it is hoping to broaden its cancer portfolio. Reports surfaced last year suggesting the firm had ...

Helix BioPharma Corp. (TSX: "HBP", OTC PINK: "HBPCD", FRANKFURT: "HBP0") ("Helix" or the "Company"), a clinical-stage oncology company shaping a near future where today's hard-to-treat cancers are ...

Vantage Market Research report examines the Antibody Drug Conjugates (ADCs) market, forecasting trends and dynamics from 2025 ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient (dMMR), surgically resectable endometrial cancer, according to findings presented at the SGO 2025 Annual ...

The energy was electrifying as some of the most influential Black healthcare leaders convened at BlackDoctor.org's Thought Leadership Summit for insightful discussions.

PE-backed specialty pharma company Kelso Pharma appointed Giovanni Mauri as general manager of its recently acquired Italian ...

Takeda Pharmaceutical Company Limited engages ... plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab ...

LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") , a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

Cullinan Therapeutics rebranded from oncology to immunology+oncology, focusing on CD19 TCEs for autoimmune diseases. Check ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team.